The interleukin (IL)-24/melanoma differentiation associated gene-7 (mda-7) is a member of the IL-10 cytokine family. Introduction of the IL-24 gene into a variety of cancer cells suppresses their growth. It has not been shown, however, whether IL-24 can suppress the growth of hepatoma cells. The purpose of this study was to determine whether the mouse (m)IL-24 gene would suppress hepatoma cells in vivo after being delivered via intramuscular electroporation. After mice were given a subcutaneous dorsal injection of ML-1 hepatoma cells, the mIL-24 gene was delivered and suppressed tumor growth. On day 140, 60% of the mIL-24-treated mice (n ¼ 10) and 0% (n ¼ 10) of the untreated control mice had survived. We also generated a mouse-hepatoma model by injecting ML-1 cells into the spleen, which resulted in tumor metastasis in the liver. Intramuscular electroporation of mIL-24 also inhibited hepatoma-cell growth in the liver. On day 50, 90% of the experimental mice (n ¼ 10) and 40% (n ¼ 10) of the control mice had survived. Liver tumors in surviving experimental mice were 50% smaller than those in control mice. IL-24 also inhibited tumor vascularization. These results suggest that IL-24 has potential therapeutic value for hepatoma.
Introduction
Interleukin (IL)-24 (melanoma differentiation associated gene (mda-7)), a member of the IL-10 family, was initially believed to induce melanocyte/melanoma-cell differentiation. Melanocytes express IL-24, but melanoma cells do not. IL-24 inhibits melanoma cell growth during the cell cycle G2/M phase. 1, 2 Many other studies have shown that IL-24 inhibits the growth of a variety of other types of tumors and that it induces apoptosis in transformed cells without negatively affecting any normal cell. [3] [4] [5] IL-24 expression was upregulated in wound healing and during the in vitro differentiation of a melanoma cell line. 6, 7 IL-24 inhibited human lungtumor growth through the inhibition of angiogenesis, demonstrating that it is a potent antiangiogenic effector. 8 In vivo electroporation has been widely used to introduce exogenous genes, including DNA, in animal models, and it provides an efficient way to analyze their effects. Gene transfer into muscle by in vivo electroporation is more efficient for producing sustained levels of therapeutic proteins, including anticancer DNA, than is a simple intramuscular DNA injection or protein injection. [9] [10] [11] [12] [13] [14] Mouse homologue IL-24 (mIL-24) was initially named FISP (IL-4-induced secreted protein) is stimulated by T-cell receptor signaling in Th2 cells. 15 However, there are no data on whether mIL-24, like human IL-24 (hIL-24), kills cancer cells. Nor are there any reports on whether IL-24 inhibits liver cancer or whether delivery of IL-24 via electroporation kill cancers. To see whether IL-24 could inhibit the growth of hepatoma cells in vivo, we used intramuscular electroporation to deliver mIL-24 genes into mice with hepatoma and then monitored the growth of their liver tumors and their survival rate.
Results
Expression of exogenous mIL-24 using in vivo intramuscular electroporation To determine whether the mouse IL-24 gene would suppress hepatoma cells in vivo after being delivered via intramuscular electroporation, we established two different models. In one model, mice were given a subcutaneous dorsal injection of ML-1 hepatoma cells. Tumor formation occurred on the backs of mice in 60 days, which was followed by mIL-24 gene delivery via intramuscular electroporation. In the second model, mice were given an intrasplenic injection with ML-1 cells, and tumor metastasis in the liver was allowed for 10 days, after which mIL-24 was delivered via intramuscular electroporation. To monitor whether systemic mIL-24 protein was expressed, mice were bled from the retroorbital plexus the second day after cDNA delivery. The serum was collected for 20 days. An ELISA analysis was performed to detect expression of exogenous mIL-24 in the mice serum. As mIL-24 cDNA vector contained a 6-His tag at its 3 0 -end, anti-His monoclonal antibody was used as detection antibody to prevent detection of endogenous mIL-24, while anti-hIL-24 polyclonal antibody was used as a capture antibody. Absorbance at OD 490 was presented to demonstrate expression of mIL-24 because recombinant mIL-24 protein was not commercially available to estimate the equivalent concentration of mIL-24 in serum. Exogenous mIL-24 protein in serum was detected after intramuscular electroporation of mIL-24 cDNA (Figure 1 ). The mIL-24 level peaked on day 18 (8th day after elctroporation) and gradually leveled off. Control groups given empty vector and saline did not express significant amounts of mIL-24.
mIL-24 inhibited ML-1 cell growth on the backs of mice At 2 months after mice were dorsally injected with ML-l cells, tumors formed on their backs. Intramuscular electroporation was used to deliver pcDNA3.1-mIL-24 into both hind limbs of the mice. The control group was injected with empty vector or PBS. In total, 140 days after injection of the ML-1 cells, 100% of the PBS-treated mice had died (Figure 2 ). In total, 30% of the empty vectortreated group survived. In contrast, 60% of the pcDNA3.1-mIL-24-treated group survived, and some of them lived for 180 days. This result demonstrated that mIL-24 could protect mice from ML-1 tumors.
To see whether survival was associated with tumor mass, tumor sizes were measured in another independent experiment. Mice were divided into four groups of 10. At 40 days after being injected with ML-1 cells, one group, the untreated control group, received no further treatment, and the other three groups were injected with PBS, empty vector, or pcDNA3.1-mIL-24. From days 60-80, tumors on the mice treated with mIL-24 were 10-20% the size of those on untreated controls. Tumors on emptyvector-treated mice were 40-60% the size of those on untreated controls (Figure 3 ). These tumors may have been smaller because the empty vector has CpG sequences that induced some immunity to the tumor. As the tumors on the mIL-24-treated mice were even smaller, the antitumor activity of pcDNA3.1-mIL-24 cannot have been caused only by the CpG sequences in the vector (Figure 3) . Figure 1 Detection of exogenous mIL-24 in mouse serum after electroporation. Mice were given an intrasplenic injection of ML-1 cells on day 0 ( ). After 10 days ( + ), pcDNA3.1-mIL-24, empty vector or saline was delivered to the muscles of both hind legs of BALB/cJ mice (n ¼ 10 in each group) via intramuscular electroporation. Electroporation was performed every other day for a total of four times for each mouse. Exogenous expression of mIL-24 was detected with ELISA system. Human IL-24 polyclonal antibody was coated on 96-well plates as capture antibody. Mouse anti-His taq monoclonal antibody was used as detection antibody for exogenous mIL-24, which was followed by a layer of HRP-conjugated goat anti-mouse IgG. The absorbance at OD 490 nm was measured. The level of mIL-24 in serum was presented as absorbance at OD490 for groups of pcDNA3.1-mIL-24 (m), pcDNA3.1 empty vector (n), or saline (J). *Po0.05 compared with empty-vector-treated controls. Figure 2 Mouse IL-24 (mIL-24) increased the survival rate in tumor-bearing mice. Survival curves were generated according to the Kaplan-Meier method, and statistical comparisons were made by use of the log-rank method. On day 0, BALB/cJ mice (n ¼ 10 in each group) were subcutaneously injected with 1 Â 10 6 ML-l cells on the back ( ). After 60 days ( + ), pcDNA3.1-mIL-24 (.), pcDNA3.1 empty vector (,), or saline (J) were delivered to the muscles of both hind legs using intramuscular electroporation. Electroporation was performed every other day on the muscles of alternate tibias for a total of four times for each mouse. Po0.05 pcDNA3.1-mIL-24 treated group compared to empty vector control group. Figure 3 Intramuscular electroporation of pcDNA3.1-IL-24 decreased tumor volume on the backs of tumor-bearing mice. BALB/ cJ mice (n ¼ 40) were subcutaneously injected with 1 Â 10 6 ML-1 cells on the back on day 0 ( ). After 40 days ( + ), the 10 control mice (n) were given no further treatment, but 10 mice were given pcDNA3.1-IL-24 (K), 10 were given pcDNA3.1 empty vector (&), and 10 were given saline (J) delivered to the muscles of both hind legs using intramuscular electroporation. Electroporation was performed every other day for a total of four times for each mouse. Tumor size (volume) was calculated as ½ðmaximum diameter of tumorÞÂðminimum diameter of tumorÞ 2 =2:
The tumor size was the average of 10 mice from each group. *Po0.05; **Po0.01 compared with empty-vector-treated controls.
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mIL-24 suppressed ML-1 tumor cell growth in a hepatoma animal model mIL-24 inhibited growth of ML-1 tumor cells on the backs of mice. To see whether it could also inhibit tumor cells grown in the liver, we generated a hepatoma animal model by injecting 1 Â 10 6 ML-1 cells into the spleens of mice. After 10 days, either empty vector or pcDNA3.1-mIL-24 was delivered into the mice via intramuscular electroporation. Survival rate was monitored for 5 months. After 50 days, 100% of the mice injected with ML-1 cells alone died, but 40% of the mice treated with empty vector survived. In contrast, 90% of the mice treated with pcDNA3.1-mIL-24 survived. Mouse IL-24 plasmid DNA alone had no effect on mice without tumors ( Figure 4 ). These results demonstrated that mIL-24 could suppress ML-1-cell growth in the liver. To analyze whether survival rate reflected the effect of mIL-24 on tumor mass, we measured the weight of liver tumors before death in another independent experiment. Mice treated similarly with ML-1 cells followed by pcDNA3.1-mIL-24 were killed on day 30, the spleen and the liver were weighed. While there was a 10% difference in the weight of the spleen between pcDNA3.1-mIL-24-treated and empty-vector-treated control mice (Figure 5a ), there was a 50% reduction in the tumor mass of the liver in the former mice compared with the latter (Figure 5b ). These data demonstrated that mIL-24 suppressed tumor growth in the liver and increased the survival of mice.
mIL-24 inhibited tumor vascularization IL-24 is a potent antiangiogenic factor. Systemic administration of IL-24 inhibits lung tumor growth in a mouse xenograft model. 8 To determine whether mIL-24 affected liver tumor vascularization, tumors established in the livers were removed, sectioned, and stained with anti-CD31 antibody. Representative liver sections from mice treated with PBS, empty vector, or pcDNA3.1-mIL-24 are shown in Figure 6a . mIL-24 therapy resulted in a statistically significant (Po0.05) 30% reduction in tumor vessel density compared with PBS and empty vector treatment, whereas there was no significant difference between tumors treated with PBS and those treated with empty vector (Figure 6b ). Survival rate of mice treated with pcDNA3.1-mIL-24 after intrasplenic injection of ML-1 cells. Survival curves were generated according to the Kaplan-Meier method, and statistical comparisons were made by use of the log-rank method. BALB/cJ mice (n ¼ 10 in each group) were given an intrasplenic injection of 1 Â 10 6 ML-1 cells on day 0 ( ). After 10 days ( + ), pcDNA3.1-mIL-24 (.) or pcDNA3.1 empty vector (,) was delivered to the muscles of both hind legs using intramuscular electroporation. Control groups included mice injected with ML-1 cells alone (') and nontumorbearing mice injected with pcDNA3.1-mIL-24 alone ( ). Electroporation was performed every other day on the muscles of alternate tibias for a total of four times for each mouse. The experiment was repeated three times with similar survival rate. Po0.05 pcDNA3.1-mIL-24 treated group compared to empty vector control group. ML-1 cells. Mice that had not been injected with ML-1 cells but that had been given, via intramuscular electroporation, pcDNA3.1 empty vector alone or pcDNA3.1-mIL-24 alone were used as negative controls. On day 40, the spleen (n ¼ 5) (a) or the liver (n ¼ 5) (b) was weighed. *Po0.05 compared with ML-1 and empty-vectortreated controls. Electroporation was performed every other day on the muscles of alternate tibias for a total of four times for each. The weight represented the average of five mice. 
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Discussion
In the present study, we found that pcDNA3.1-mIL-24 plasmid DNA delivered into mice via intramuscular electroporation suppressed the growth of liver tumor cells and prolonged the life span of mice with cancer. Delivery of cytokine genes using in vivo electroporation dramatically increases gene expression in muscle tissue. 14 In our study, IL-24 protein was detectable in the serum of mice after delivery of plasmid DNA via intramuscular electroporation, and the expression level peaked on the eighth day after delivery and gradually leveled off. As mIL-24 recombinant protein is not commercially available, we could not estimate the equivalent concentration of mIL-24 in the serum. In addition, we used anti-hIL-24 polyclonal antibody as a capture antibody for mIL-24, which might have affected the affinity between antibody and antigen. Thus, the absorbance reading at OD 490 from the ELISA result might have been lower than the true level. Nevertheless, electroporation of pcDNA3.1-mIL-24 significantly decreased tumor size and increased the survival rate in a mouse hepatoma model. We speculate that mIL-24 may affect early tumor formation, vascularzation, and metastasis.
The data also demonstrated that injection of empty vector (pcDNA3.1) suppressed some tumor-cell growth both on the backs and in the livers of mice. This might have been due to the CpG dinucleotide sequence (CpG motifs) present in the empty vector. The immune system of vertebrates recognizes CpG motifs, which regulate several immune responses. This recognition is mediated by a molecular-pattern-recognition receptor: toll-like receptor (TLR) 9, which initiates a signaling pathway that activates several transcription factors, including NF-kB and AP-1. The immunological events that occur after CpG DNA activation of the immune system include B-cell proliferation, increased expression of MHC class II antigens, increased synthesis of RNA and DNA, and the release of cytokines and chemokines. 16 The potent T-helper-1 immune response produced by CpG activation can induce immunity and therefore have a protective effect against cancer. 17 The mechanism by which IL-24 suppresses the growth of liver tumor cells is not clear. Recently, IL-24 was identified as a novel and potent antiangiogenic factor because systemic administration of IL-24 inhibited lung tumor growth in a mouse xenograft model. 8 We showed that mIL-24 gene delivered by intramuscular electroporation inhibited tumor vascularization in the liver. This further confirmed the antiangiogenesis activity of IL-24 in vivo. Alternatively, IL-24 may suppress tumor growth by induction of cell apoptosis. Further study using mouse recombinant protein of mIL-24 is required to clarify this mechanism in vitro and in vivo when mIL-24 protein is available in the future.
IL-24 induced cell apoptosis through intracellular and receptor-dependent pathways. 18 In receptor-negative cells, IL-24 induced cell apoptosis through an intracellular pathway by activating PKR, p38 MAPK, and the ER stress pathway in NSCLC cells such as A549 and H1299. In receptor-positive cells, IL-24 induced apoptosis through a receptor-dependent and STAT3-independent pathway in melanoma cells. IL-24-induced receptordependent apoptosis is reversed by IL-20R1 antibody. 19 Our RT-PCR data demonstrated two types of receptor-IL-20R1/IL-20R2 and IL-22R/IL-20R2-expressed on ML-1 cells.
Immunocytochemical staining also showed IL-20R1/ IL-20R2 expressed on the cell surface of ML-1 cells. These data further confirm that ML-1 cells could be a target of IL-24. Thus, the tumor suppression effect may go through a receptor-dependent pathway. We also detected hIL-24 receptors on two human hepatoma cell lines, HepG2 and Huh-7 by RT-PCR (data not shown). Therefore, IL-24 may have therapeutic potential in human liver cancer.
Recently, the rat gene MOB-5, a homologue of IL-24, was reported to exhibit antitumor activity. 20 No anticancer function has been reported for mIL-24 so far. This study is the first to demonstrate that mIL-24 suppresses tumor growth in vivo.
In summary, we have demonstrated that mIL-24 suppresses the ML-1 liver tumor grown either on the backs or in the livers of mice. The suppression also increased the survival rate and prolonged the life span of mice with liver tumors. We also demonstrated that mIL-24 can be delivered in vivo using intramuscular electroporation. This method of gene therapy has several advantages over recombinant protein delivery or virusmediated gene delivery, and it showed similar protective effects against cancer in mice.
Materials and methods
Experimental animals
Female BALB/cJ mice (age: 8-12 weeks old; weight: 18-20 g) were purchased from the laboratory animal center of our institution. The animals were housed together in temperature-and humidity-controlled quarters (251C; 50% humidity) with a 12/12-h light/dark cycle and free access to food and water. Acquisition, care, use, and disposition of these animals conformed to the established guidelines of our medical college. The mice were divided into groups of 10 for survival-rate study and five for tumor-mass study.
Plasmid DNA preparation Mouse IL-24 was constructed by inserting mIL-24 cDNA with a hexa-histidine tag at its 3 0 -end into the unique HindIII and NotI site of pcDNA3.1 expression vector (Invitrogen Corp., Carlsbad, CA, USA) containing cytomegalovirus (CMV) promoter. The full-length of mIL-24 was amplified with PCR using the sense primer: 5 0 -cccaa gcttatgagttggggactacagatt-3 0 and the antisense primer: 5 0 -tttgcggccgctcaatgatgatgatgatgatggagatggtagaatttctgcatc-3 0 .
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The plasmids (p) pcDNA3.1-mIL-24 and pcDNA3.1 (empty vector) were purified using commercial kits (QIAfilter Plasmid Maxi Kits; QIAGEN Inc., Valencia, CA, USA) followed by isopropanol precipitation phenol/ chloroform extraction, and ethanol precipitation. DNA was dissolved in saline (0.85% NaCl), and its quantity was assessed using a fluorometer (DyNA Quant 200; Amersham Biosciences Corp., Piscataway, NJ, USA). The purity of the plasmid was confirmed using 1% agarose gel electrophoresis.
Intramuscular electroporation
Mice were anesthetized using intraperitoneally injected acepromazine maleate (2 ml/kg) (Tech America, Elwood, KS, USA). A 50-ml formulation containing 50 mg of plasmid DNA (either pcDNA3.1-mIL-24 or empty vector) or phosphate-buffered saline (PBS) control was injected intramuscularly into the bilateral quadriceps muscle of each animal with a 27-gauge needle. Immediately after injection, transcutaneous electric pulses were applied using a Genetrode (Model 508(S); BTX, San Diego, CA, USA). Electrical contact with the leg skin was ensured by shaving each leg. Electric pulses were delivered using an electric pulse generator (Electro Square Porator ECM 830; BTX). Voltage remained constant during the pulse. Electrodes consisted of a pair of stainless steel needles 5 mm in length and 0.4 mm in diameter with a fixed 5-mm distance between them. Six pulses (rate: 1 pulse/s; duration: 100 ms/pulse) of the indicated voltage (100 or 900 V) were administered to each injection site. 9 Electroporation was performed every other day on the muscles of alternate tibias for a total of four times for each mouse in each experiment.
Generation of tumor on the back of mice
The ML-1 cell line is an immortalized well-differentiated mouse hepatocyte cell line derived from BALB/cJ mice. Generation of mouse hepatoma model To generate a mouse hepatoma model, induction of in situ hepatoma transplantation in murine liver was performed. An in situ growth of ML-1 cells in the liver of BALB/c mice was developed. 21 ML-l cell was grown in Dulbecco's modified Eagle medium (DMEM) with 10% fetal bovine serum (FBS). To induce tumor formation in the liver, 3 Â 10 6 ML-1 cells were injected into the spleen, where they colonized for 2 or 3 days, and then expanded gradually and migrated toward the liver, lungs, or intestine. Tumor nodules were found in the liver 2 weeks postinjection. At 10 days after injection of ML-1cells, pcDNA3.1-mIL-24 or empty vector was injected into mice using intramuscular electroporation. After 1 month, tumor mass was analyzed by weighing the liver and spleen after killing the mice. The survival rates of the mice were recorded in another independent experiment.
Detection of exogenous mIL-24 in mice serum by ELISA The injected mIL-24 cDNA contained a 6-His tag at its 3 0 -end. Therefore, anti-His taq monoclonal antibody was used as the detecting antibody to prevent detection of endogenous mIL-24. Human IL-24 polyclonal antibody (AF1965, R&D Systems, Minneapolis, MN, USA) (capture antibody) was coated onto 96-well plates for 16 h at 41C. The coated plates were washed three times with PBST buffer containing PBS and 0.1% Tween-20. To avoid nonspecific binding, the plates were incubated with blocking solution (PBST buffer plus 5% skim milk) for 2 h at 371C. Serum samples were added into the wells and incubated for 2 h at 371C. After it was washed, anti-His taq monoclonal antibody (detection antibody) was added to the plate for 1 h at 371C, followed by HRP-conjugated goat anti-mouse IgG (Chemicon International) for another 1 h at 371C. For detection of the HRP level, o-Phenylenediamine(OPD) was added to the plate, and the mixture was incubated for 15 min at 371C. The reaction was stopped by adding 10% H 2 SO 4 . The absorbance at an optical density of 490 nm of the mixture was measured. The level of mIL-24 in serum was shown as OD 490 . Detection of receptor expression using immunocytochemical staining Commercially available hIL-20R1 monoclonal antibody characterized as able to recognize both human and mouse IL-20R1 (clone 173707; R&D Systems, Minneapolis, MN, USA) was used for immunohistochemical staining. IL-20R2 polyclonal antibody was generated by immunizing rabbits with soluble hIL-20R2 extracellular domain following the standard protocol. The polyclonal antibody was purified using protein-A affinity chromatography. For immunocytochemical staining, ML-1 cells grown on plastic slides (Lab-Tek chamber slides; Electron Microscopy Sciences, Hatfield, PA, USA) were washed twice in PBS and fixed in 4% paraformaldehyde for 10 min, then permeabilized using PBS with 0.1% Triton X-100. Nonspecific binding sites were blocked by incubating the slides first in PBS/BSA (0.1% w/v), then with primary antibodies (IL-20R1 monoclonal or IL-20R2 polyclonal antibody) for 1 h at room temperature, and with the secondary antibody. Cells incubated with mouse isotype IgG1 or rabbit preimmune serum were used as negative controls. For blood-vessel staining, frozen sections from the livers of tumor-bearing mice were stained with anti-CD31 monoclonal antibody (CD31; PharMingen, San Diego, CA, USA). Slides were incubated with the diaminobenzidine DAB substrate kit (Vector Laboratories, Burlingame, CA, USA) and counterstained with Mayer's hematoxylin (ThermoShandon, Pittsburgh, PA, USA).
Detection of gene expression using RT-PCR
Statistical analysis
Significant difference was detected with Student's t-test using a statistical software package in Microsoft Excel. Kaplan-Meier estimates of overall survival time in the various groups were compared using the log-rank test. Results are given as mean7s.d. (unless otherwise indicated), and statistical significance was set at Po0.05.
